|
Indications and Dosage
Intravenous
Nausea and vomiting associated with cancer chemotherapy Adult: 300 mcg once daily. May administer an additional dose of 300 mcg if necessary. Max: 600 mcg/day. Oral Nausea and vomiting associated with cancer chemotherapy Adult: 100 mcg once daily. Oral Irritable bowel syndrome in men Adult: 5 mcg once daily, may adjust dose according to symptoms. Max: 10 mcg/day.
|
|
Administration
May be taken with or without food.
|
|
Incompatibility
D-mannitol inj, bumetanide inj and furosemide inj.
|
|
Special Precautions
Elderly; Pregnancy. Not recommended in lactation. Safety and efficacy in paediatric population has not been established.
|
|
Adverse Reactions
Headache, diarrhoea, constipation, rash, itching, redness, heat, hot flushes, hiccup, numbness of tongue, hepatic dysfunction (increased AST, ALT, GPT, and bilirubin), increased BUN. Epileptiform attacks have been reported with other 5-HT3 antagonists.
Potentially Fatal: Shock or anaphylactoid symptoms may occur. |
|
Drug Interactions
May increase plasma concentration when given with fluvoxamine (CYP1A2 inhibitor).
|
|
Action
Description:
Mechanism of Action: Ramosetron is a 5-HT3 receptor antagonist. It exerts its antiemetic property by blocking of serotonin to 5-HT3 receptors present in the afferent vagal nerve-endings in the GI mucosa. Pharmacokinetics: Metabolism: Hepatic metabolism mainly via CYP1A2 and CYP2D6 enzymes. Excretion: Excreted in urine as unchanged drug (16-22% within 24 hr following IV admin), demethylated and hydroxylated metabolites and their conjugates. βphase elimination half-life: About 5 hr. |
|
Storage
Intravenous:
Store in light-proof containers at room temperature. |
|
MIMS Class
|
Sign Out
